Noxopharm reports preclinical data revealing SOF-SKN’s active ingredient remains in skin tissues for about 3.5 days with minimal systemic absorption, supporting less frequent dosing and sustained activity for cutaneous lupus treatment.
- SOF-16 half-life in skin approximately 3.5 days
- Drug localised in epidermis and dermis with negligible bloodstream absorption
- Findings support potential for less frequent dosing schedules
- Data underpin preparations for upcoming human clinical trial
- SOF-SKN targets $3.3 billion cutaneous lupus market initially
Prolonged Skin Retention Validates SOF-SKN’s Targeted Approach
Noxopharm Limited (ASX:NOX) has unveiled encouraging preclinical pharmacokinetic data for SOF-SKN™, its lead candidate for treating cutaneous lupus erythematosus (CLE). The active molecule, SOF-16, demonstrated a skin half-life of roughly 3.5 days in both normal and disease-like skin models, suggesting the drug remains in the target tissue far longer than daily dosing intervals. This persistence could translate into more sustained therapeutic effects and improved patient compliance through less frequent application.
Importantly, the study confirmed SOF-16’s confinement to the epidermis and dermis layers, with systemic absorption falling below quantifiable levels at all measured time points. This pharmacological profile aligns with SOF-SKN’s design to suppress local immune activation without inducing systemic immunosuppression, a common challenge in autoimmune therapies.
Data Supports Regulatory Submission and Trial Planning
The dosing regimen insights gleaned from this animal model study are a critical component of Noxopharm’s strategy to advance SOF-SKN into human clinical trials. The company is actively engaging a Contract Research Organisation (CRO) to support trial preparations, marking a clear progression from the recently completed Phase 1 HERACLES safety trial. These developments follow the leadership transition where Dr Olivier Laczka, previously Chief Scientific Officer, was appointed CEO to accelerate the Sofra™ platform’s growth, underpinning the company’s clinical and commercial ambitions.
SOF-SKN’s promising pharmacokinetics complement the broader Sofra™ technology platform’s innovative approach to modulating immune responses at their source. This platform recently received significant scientific validation with a publication in Nature Immunology, reinforcing its potential across multiple autoimmune and inflammatory diseases.
Market Potential and Future Indications
Initially targeting the $3.3 billion global CLE market, Noxopharm envisions expanding SOF-SKN’s application to other autoimmune skin diseases such as psoriasis and dermatomyositis. The company’s proprietary Sofra™ platform also holds promise for systemic autoimmune conditions including rheumatoid arthritis and diabetes, positioning Noxopharm in a growing sector expected to reach over US$219 billion by 2035.
While these preclinical results are encouraging, the translation of skin retention and localised activity into clinical efficacy remains to be demonstrated. The upcoming human trials will be pivotal in confirming SOF-SKN’s therapeutic profile and dosing convenience, factors that could differentiate it in a competitive autoimmune dermatology landscape.
Bottom Line?
SOF-SKN’s extended skin residence and minimal systemic exposure set a promising foundation, but clinical validation will be essential to unlock its potential in chronic autoimmune skin conditions.
Questions in the middle?
- Will SOF-SKN’s prolonged skin retention translate into improved clinical outcomes in human trials?
- How might less frequent dosing impact patient adherence and market competitiveness?
- What regulatory hurdles remain before SOF-SKN can advance beyond early-stage clinical development?